A pilot study to assess the effect of regulatory T cell depletion on 5T4-containing MVA (TROVAX) vaccination in patients with INOPERABLE metastatic colorectal cancer.
Phase of Trial: Phase I/II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs MVA 5T4 (Primary) ; Cyclophosphamide
- Indications Colorectal cancer
- Focus Pharmacodynamics
- Acronyms TaCTiCC
- 17 Mar 2017 Results have been published in an Oxford BioMedica financial report.
- 17 Mar 2017 According to an Oxford BioMedica media release, data from the study has been presented in a oster at the American Society of Clinical Oncology and Society for Immunotherapy of Cancer (ASCO-SITC) symposium.
- 15 Apr 2016 Status changed from recruiting to completed.